Nilotinib Teva (Nilotinib Hydrochloride Dihydrate)

Nilotinib Teva is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in Philadelphia chromosome‑positive leukemias.

• Chronic myeloid leukemia (CML) – chronic phase: achieves hematologic and cytogenetic responses and slows disease progression.
• CML – accelerated phase: provides disease control after failure of prior tyrosine‑kinase inhibitor therapy.
• CML with prior imatinib resistance: offers an alternative targeted option for patients who have not responded to first‑generation inhibitors.

• Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL fusion protein, inhibiting its tyrosine‑kinase activity. This blocks downstream signaling pathways that drive proliferation and survival of Philadelphia chromosome‑positive leukemic cells, leading to reduced tumor growth and increased apoptosis.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools occurring intermittently.
• Rash: skin redness or itching.
• Fatigue: decreased energy levels.
• Headache: mild to moderate head pain.
• Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects

• QT interval prolongation: may lead to cardiac arrhythmias.
• Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain.
• Hepatic toxicity: elevated liver enzymes or liver injury.
• Severe neutropenia: marked reduction in white blood cells.
• Cardiovascular events: including arterial occlusive disease.

Patients receiving Nilotinib should be monitored for specific safety concerns.

• Cardiac monitoring: obtain baseline ECG and monitor QT interval regularly.
• Hepatic function: check liver enzymes before initiation and periodically during therapy.
• Pancreatic enzymes: assess amylase and lipase at baseline and as clinically indicated.
• Hematologic parameters: monitor complete blood count for neutropenia or thrombocytopenia.
• Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors and QT‑prolonging agents.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Nilotinib has a notable potential for drug‑drug interactions that require careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure and toxicity.
• QT‑prolonging medications (e.g., amiodarone, sotalol): can exacerbate cardiac risk.
• Antacids or proton‑pump inhibitors that raise gastric pH: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): can lower nilotinib concentrations.
• Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for increased statin levels and muscle toxicity.